Cookies?
Library Header Image
LSE Research Online LSE Library Services

Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis

Vermersch, Patrick, Martinelli, Vittorio, Pfleger, Claudia, Rieckmann, Peter, Alonso-Magdalena, Lucia, Galazka, Andrew, Dangond, Fernando and Phillips, Lawrence D. (2019) Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis. Clinical Therapeutics, 41 (2). pp. 249-260. ISSN 0149-2918

[img] Text
Pending embargo until 1 January 2100.

Download (824kB) | Request a copy
[img] Text (BenefitRisk) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB)

Identification Number: 10.1016/j.clinthera.2018.12.015

Abstract

Purpose: We applied Multi-Criteria Decision Analysis (MCDA) methods in a structured benefit–risk assessment of cladribine and newer approved disease-modifying drugs (DMDs) for patients with relapsing-remitting multiple sclerosis (RRMS). Methods: Decision conferencing with clinical neurologists as decision makers was used to create an MCDA model that incorporated available evidence on DMDs for RRMS and clinical judgments about the relevance of the evidence. Benefit–risk assessments were conducted for DMDs in both patients with RRMS and patients with RRMS with high disease activity (HDA; defined as ≥2 relapses in the previous year). Treatment options included cladribine and recently approved DMDs available in European Union countries at the time of assessment (December 2015): alemtuzumab, dimethyl fumarate, fingolimod, natalizumab, and teriflunomide. To account for the relative importance of DMD effects, scores for the MCDA model were weighted to ensure that the most clinically important attributes carried more weight in the final benefit–risk calculation. The neurologists weighted different efficacy and safety profile attributes without any reference to individual DMDs to disassociate the assessment of weights with any specific DMD. The neurologists did not do direct comparisons between DMDs. Findings: The highest overall weighted preference value for the RRMS model was for dimethyl fumarate (63) followed closely by cladribine (62). For patients with RRMS and HDA, cladribine had the highest overall weighted preference value (76), followed by alemtuzumab (62) and natalizumab (61). The benefit–risk balance of cladribine in patients with RRMS and specifically patients with RRMS who exhibited HDA characterized by high relapse activity (≥2 relapses in the previous year) was more favorable than the other DMDs included in the model. Implications: The balance of high efficacy and the safety profile makes cladribine an important treatment option to consider, both in patients with RRMS and patients with HDA. Regular, single-country meetings could be organized to explore how differences in cultural values (scores and weights) and updated input data might affect the usefulness of MCDA in different, real-world, dynamic clinical settings.

Item Type: Article
Official URL: https://www.journals.elsevier.com/clinical-therape...
Additional Information: © 2019 Elsevier Inc.
Divisions: Management
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Sets: Departments > Management
Date Deposited: 07 Jan 2019 15:01
Last Modified: 15 Sep 2019 23:07
URI: http://eprints.lse.ac.uk/id/eprint/91544

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics